Skip to main content
Top
Published in: Experimental Hematology & Oncology 1/2023

Open Access 01-12-2023 | Neutropenia | Correspondence

New approaches to idiopathic neutropenia in the era of clonal hematopoiesis

Authors: Olisaemeka D. Ogbue, Tariq Kewan, Waled S. Bahaj, Carmelo Gurnari, Valeria Visconte, Jaroslaw P. Maciejewski

Published in: Experimental Hematology & Oncology | Issue 1/2023

Login to get access

Abstract

Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell clonopathy of undetermined significance, found in 37% and 8% of cases, respectively. Patients with neutropenia also had hypogammaglobulinemia (6%) and/or monoclonal gammopathy of undetermined significance (5%). NGS application has further broadened the spectrum of causes of CIN by including manifestations of clonal hematopoiesis, present in 12% of cases. TET2 (3%), TP53 (2%), and IDH1/IDH2 (2%) mutations were the most commonly found and were enriched in cases with T-LGL. We show that these clinico-molecular associations can be simultaneously present, complicating a proper diagnostic distinction within the broader entity of seemingly idiopathic neutropenia of autoimmune origin. Identification of etiologic culprits may also guide rational selection of therapies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sicre de Fontbrune F, Moignet A, Beaupain B, et al. Severe chronic primary neutropenia in adults: report on a series of 108 patients. Blood. 2015;126:1643–50.CrossRefPubMed Sicre de Fontbrune F, Moignet A, Beaupain B, et al. Severe chronic primary neutropenia in adults: report on a series of 108 patients. Blood. 2015;126:1643–50.CrossRefPubMed
2.
go back to reference Bareau B, Rey J, Hamidou M, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica. 2010;95:1534–41.CrossRefPubMedPubMedCentral Bareau B, Rey J, Hamidou M, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica. 2010;95:1534–41.CrossRefPubMedPubMedCentral
3.
go back to reference Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood. 1994;84:1620–7.CrossRefPubMed Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood. 1994;84:1620–7.CrossRefPubMed
4.
go back to reference Clemente MJ, Wlodarski MW, Makishima H, et al. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood. 2011;118:4384–93.CrossRefPubMedPubMedCentral Clemente MJ, Wlodarski MW, Makishima H, et al. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood. 2011;118:4384–93.CrossRefPubMedPubMedCentral
5.
go back to reference Wlodarski MW, Nearman Z, Jiang Y, Lichtin A, Maciejewski JP. Clonal predominance of CD8(+) T cells in patients with unexplained neutropenia. Exp Hematol. 2008;36:293–300.CrossRefPubMedPubMedCentral Wlodarski MW, Nearman Z, Jiang Y, Lichtin A, Maciejewski JP. Clonal predominance of CD8(+) T cells in patients with unexplained neutropenia. Exp Hematol. 2008;36:293–300.CrossRefPubMedPubMedCentral
6.
go back to reference Zawit M, Bahaj W, Gurnari C, Maciejewski J. Large granular lymphocytic leukemia: from immunopathogenesis to treatment of refractory disease. Cancers. 2021;13:4418.CrossRefPubMedPubMedCentral Zawit M, Bahaj W, Gurnari C, Maciejewski J. Large granular lymphocytic leukemia: from immunopathogenesis to treatment of refractory disease. Cancers. 2021;13:4418.CrossRefPubMedPubMedCentral
7.
go back to reference Tsaknakis G, Galli A, Papadakis S, et al. Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia. Blood. 2021;138:1249–57.CrossRefPubMed Tsaknakis G, Galli A, Papadakis S, et al. Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia. Blood. 2021;138:1249–57.CrossRefPubMed
9.
go back to reference Bravo-Perez C, Carrillo-Tornel S, Garcia-Torralba E, Jerez A. Persistent large granular lymphocyte clonal expansions: “the root of many evils”-and of some goodness. Cancers. 2022;14:1340.CrossRefPubMedPubMedCentral Bravo-Perez C, Carrillo-Tornel S, Garcia-Torralba E, Jerez A. Persistent large granular lymphocyte clonal expansions: “the root of many evils”-and of some goodness. Cancers. 2022;14:1340.CrossRefPubMedPubMedCentral
10.
go back to reference Sanikommu SR, Clemente MJ, Chomczynski P, et al. Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leuk Lymphoma. 2018;59:416–22.CrossRefPubMed Sanikommu SR, Clemente MJ, Chomczynski P, et al. Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leuk Lymphoma. 2018;59:416–22.CrossRefPubMed
Metadata
Title
New approaches to idiopathic neutropenia in the era of clonal hematopoiesis
Authors
Olisaemeka D. Ogbue
Tariq Kewan
Waled S. Bahaj
Carmelo Gurnari
Valeria Visconte
Jaroslaw P. Maciejewski
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Experimental Hematology & Oncology / Issue 1/2023
Electronic ISSN: 2162-3619
DOI
https://doi.org/10.1186/s40164-023-00403-4

Other articles of this Issue 1/2023

Experimental Hematology & Oncology 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine